Coagulation Disorders and the Risk of Retinal Vein Occlusion
Overview
Hematology
Affiliations
Over the past years, there has been a dramatic increase in the number of identifiable causes of thrombophilia. However, to date, there are no large, prospective studies to assess an optimal, cost-effective approach with regard to screening and case finding for thrombophilic risk factors in patients presenting with retinal vessel occlusion. Two hundred twenty-eight patients with retinal vein occlusion (RVO) and 130 age-matched healthy controls were prospectively screened for thrombophilic risk factors. Both cohorts were divided into three subgroups, depending on the patients' age at the time of the RVO or a previous thromboembolic event. Patient age < or =45 years was associated with a high prevalence of coagulation disorders (p<0.0001). Among patients < or =45 years and >45 to < or =60 years, a family history of thromboembolism was strongly associated with the presence of thrombophilic disorders. The absence of cardiovascular risk factors was found to be a strong predictor for the presence of coagulation disorders in all patient groups (< or =45 years, p=0.003; >45 to < or =60 years, p=0.0008; >60 years, p=0.001). Multivariate analysis revealed the presence of resistance to activated protein C (p=0.014), antiphospholipid antibodies (p=0.022), and deficiency of the anticoagulant proteins (p=0.05) as independent risk factors for the development of RVO among patients < or =45 years. Our results indicate that thrombophilic disorders are associated with the development of retinal vein occlusion in patients < or =45 years by the time of the RVO or a previous thromboembolic event, in patients with a family history of thromboembolism, or in patients without cardiovascular risk factors.
Systemic Risk Factors in Branch Retinal Vein Occlusion: a Comprehensive Review.
Garnavou-Xirou C, Bontzos G, Smoustopoulos G, Velissaris S, Papadopoulos A, Georgopoulos E Maedica (Bucur). 2024; 19(2):380-387.
PMID: 39188832 PMC: 11345058. DOI: 10.26574/maedica.2024.19.2.380.
Electrochemical Monitoring in Anticoagulation Therapy.
Mruthunjaya A, Torriero A Molecules. 2024; 29(7).
PMID: 38611733 PMC: 11012951. DOI: 10.3390/molecules29071453.
[Cardiovascular risk factors, haemostasis and antithrombotic treatment in retinal vessel occlusion].
Kuhli-Hattenbach C, Sucker C, Feltgen N, Spitzer M, Schultheiss M, Hattenbach L Ophthalmologie. 2022; 119(11):1129-1139.
PMID: 36344732 DOI: 10.1007/s00347-022-01751-y.
Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.
Tang Y, Cheng Y, Wang S, Wang Y, Liu P, Wu H Front Med (Lausanne). 2022; 9:910600.
PMID: 35783660 PMC: 9240302. DOI: 10.3389/fmed.2022.910600.
Paciullo F, Valeriani E, Porfidia A, Di Nisio M, Donadini M, Marcucci R Blood Transfus. 2022; 20(4):341-347.
PMID: 35175186 PMC: 9256508. DOI: 10.2450/2022.0276-21.